<DOC>
	<DOCNO>NCT00937391</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics , safety efficacy Magnevist child 2 month &lt; 2 year age</brief_summary>
	<brief_title>Contrast-enhanced MRI Children 2 Months &lt; 2 Years</brief_title>
	<detailed_description>Safety issue address AE section</detailed_description>
	<criteria>Age : 2 month &lt; 2 year ( 23 month ) Participants ( male/female ) schedule undergo gadoliniumenhanced MRI Able comply study procedure Clinical unstable participant ( eg , intensive care unit ) Renal Insufficiency Participants undergo chemotherapy &lt; /= 48 hour prior 24 hour administration Magnevist .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>MRI agent</keyword>
	<keyword>Magnevist</keyword>
</DOC>